In the hunt for an antigen in solid tumors that CAR-T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
With RNA sequencing and other data, researchers gauged neoantigen formation, immunoediting, and clonal evolution in non-small cell lung cancers.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
In Science this week: a pair of papers finds cytosine base editors can generate off-target mutations, and more.
Researchers will first compare liquid with tissue-based tumor profiling before implementing it as a way to enroll patients into the targeted drug trials.
Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
In Nature this week: genomic factors that influence glioblastoma response to anti-PD-1 therapy, sequencing test for infectious disease, and more.
Researchers identified PTEN mutations, MAP kinase pathway alterations, and other features linked to anti-PD-1 response in individuals with the brain cancer.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.